Your browser doesn't support javascript.
loading
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Salawu, Abdulazeez; Wang, Ben X; Han, Ming; Geady, Caryn; Heirali, Alya; Berman, Hal K; Pfister, Thomas D; Hernando-Calvo, Alberto; Al-Ezzi, Esmail Mutahar; Stayner, Lee-Anne; Gupta, Abha A; Ayodele, Olubukola; Lam, Bernard; Hansen, Aaron R; Spreafico, Anna; Bedard, Philippe L; Butler, Marcus O; Avery, Lisa; Coburn, Bryan; Haibe-Kains, Benjamin; Siu, Lillian L; Abdul Razak, Albiruni R.
Afiliação
  • Salawu A; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Wang BX; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Han M; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Geady C; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Heirali A; Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Berman HK; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Pfister TD; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Hernando-Calvo A; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Al-Ezzi EM; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Stayner LA; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Gupta AA; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Ayodele O; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Lam B; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Hansen AR; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Spreafico A; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Bedard PL; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Butler MO; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Avery L; Department of Statistics, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Haibe-Kains B; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Siu LL; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Abdul Razak AR; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Clin Cancer Res ; 29(20): 4128-4138, 2023 Oct 13.
Article em En | MEDLINE | ID: mdl-37566240
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article